IL-6 Binding Polypeptide Complex for Inflammatory Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory and autoimmune disorders, such as rheumatoid arthritis, often rely on single-target approaches that may not effectively address the complex regulation of inflammatory pathways, leading to limitations in treatment efficacy and specificity.
Innovation Solution
Development of a multispecific agent, comprising an engineered polypeptide with affinity for interleukin-6 (IL-6) and an antibody or antigen binding fragment, utilizing a specific IL-6 binding motif to target both IL-6 and additional antigens associated with inflammatory and autoimmune disorders, thereby offering a dual or multiple affinity mechanism for therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-target therapy approaches are used, then treatment simplicity is maintained, but treatment efficacy is limited due to inability to address complex inflammatory pathway regulation
Solution Approach 1:
The patent applies multi-functionality by designing a bispecific antibody that can simultaneously bind to two different antigens (IL-6 and another inflammatory marker). This allows a single therapeutic agent to perform multiple functions: blocking IL-6 signaling while also targeting additional inflammatory pathways, thereby improving treatment efficacy without requiring multiple separate therapies
Solution Approach 2:
The invention merges two specific binding functions into a single antibody molecule. The bispecific antibody structure combines two different antigen-binding sites within one molecular entity, enabling simultaneous targeting of multiple inflammatory pathways and achieving synergistic therapeutic effects
2Reliability
If single-target antibodies are used, then manufacturing simplicity is maintained, but treatment specificity is insufficient for complex inflammatory disorders
Solution Approach 1:
The bispecific antibody provides enhanced treatment specificity by simultaneously targeting multiple inflammatory markers. This multi-specificity allows the single therapeutic agent to address complex inflammatory disorders more precisely than single-target antibodies, improving disease control while maintaining a unified manufacturing approach
3Adaptability or versatility
If multiple separate therapies are used to target different inflammatory pathways, then treatment coverage is improved, but device complexity and patient burden increase
Solution Approach 1:
The patent merges multiple therapeutic functions into a single bispecific antibody molecule. By combining two different antigen-specific binding sites in one molecule, the therapy achieves broad treatment coverage across multiple inflammatory pathways while simplifying the overall therapy structure from multiple separate agents to one unified agent
Solution Approach 2:
The bispecific antibody serves as a universal therapeutic agent that can simultaneously address multiple inflammatory pathways. This multi-functional design provides comprehensive treatment coverage for complex inflammatory disorders while maintaining a simple single-agent therapy regimen for patients
Data Source
AI summary
The present disclosure relates to complex comprising an engineered polypeptide having affinity for interleukin-6 (in the following referred to as IL-6) and an antibody or an antigen binding fragment thereof, wherein said engineered polypeptide having affinity for IL-6 belongs to a class of engineered polypeptides comprising the sequence EEX3X4AWX7EIHX11 LPN-LX16X17X18QX20X21AFIX25X26LX28X29. The present disclosure also relates to the use of said complex as a therapeutic agent.